Prevalence of Delta-Like Protein 3 in a Consecutive Series of Surgically Resected Lung Neuroendocrine Neoplasms.
biomarker
delta-like protein 3
immunohistochemistry
lung neuroendocrine tumors
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
06
2021
accepted:
13
08
2021
entrez:
27
9
2021
pubmed:
28
9
2021
medline:
28
9
2021
Statut:
epublish
Résumé
Delta-like protein 3 (DLL3) is a protein of the Notch pathway, and it is a potential therapeutic target for high-grade lung neuroendocrine tumors (NETs), i.e., small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC). However, DLL3 prevalence in lung NETs and its association with clinicopathological characteristics and prognosis remained unclear. We analyzed the immunohistochemical expression of DLL3 and its prognostic role in a consecutive series of 155 surgically resected lung NETs, including typical carcinoid (TC), atypical carcinoid (AC), LCNEC, and SCLC patients. The DLL3 expression was categorized as high (>50% positive tumor cells) or low (<50%). In addition, tumors were categorized by H-score (i.e., percentage of positive cells by staining intensity, ≥150
Identifiants
pubmed: 34568063
doi: 10.3389/fonc.2021.729765
pmc: PMC8458735
doi:
Types de publication
Journal Article
Langues
eng
Pagination
729765Informations de copyright
Copyright © 2021 Alì, Di Stefano, Poma, Ricci, Proietti, Davini, Lucchi, Melfi and Fontanini.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncotarget. 2017 Sep 1;8(43):73419-73432
pubmed: 29088717
Arch Pathol Lab Med. 2010 Nov;134(11):1628-38
pubmed: 21043816
Lung Cancer. 2019 Dec;138:102-108
pubmed: 31678831
Cancer Sci. 2019 May;110(5):1599-1608
pubmed: 30874360
Medicine (Baltimore). 2018 Dec;97(51):e13442
pubmed: 30572444
Thorac Cancer. 2020 Sep;11(9):2561-2569
pubmed: 32691982
Clin Cancer Res. 2021 Mar 1;27(5):1526-1537
pubmed: 33203642
Clin Cancer Res. 2019 Dec 1;25(23):6958-6966
pubmed: 31506387
Drugs R D. 2018 Dec;18(4):255-258
pubmed: 30232719
Rev Endocr Metab Disord. 2017 Dec;18(4):433-442
pubmed: 28868578
Nat Rev Mol Cell Biol. 2016 Nov;17(11):722-735
pubmed: 27507209
Diagn Pathol. 2019 May 20;14(1):47
pubmed: 31109352
Lancet Oncol. 2017 Jan;18(1):42-51
pubmed: 27932068
Endocr Pathol. 2021 Mar;32(1):154-168
pubmed: 33641055
Mayo Clin Proc. 2019 Aug;94(8):1599-1622
pubmed: 31378235
Cancer Sci. 2019 Oct;110(10):3122-3131
pubmed: 31369178
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Ann Oncol. 2015 Aug;26(8):1604-20
pubmed: 25646366
J Thorac Dis. 2018 Oct;10(Suppl 29):S3528-S3532
pubmed: 30510790
Sci Transl Med. 2015 Aug 26;7(302):302ra136
pubmed: 26311731
Hum Pathol. 2021 Feb;108:84-92
pubmed: 33245986
Nat Commun. 2019 Aug 20;10(1):3407
pubmed: 31431620
Front Oncol. 2016 Apr 14;6:94
pubmed: 27148486
Medicine (Baltimore). 2016 May;95(20):e3715
pubmed: 27196489
JAMA Oncol. 2017 Oct 1;3(10):1335-1342
pubmed: 28448665
Hum Mol Genet. 2011 Mar 1;20(5):905-16
pubmed: 21147753
Curr Treat Options Oncol. 2020 Aug 29;21(11):86
pubmed: 32862320
Lung Cancer. 2020 Sep;147:237-243
pubmed: 32745892
Surg Pathol Clin. 2019 Dec;12(4):1055-1071
pubmed: 31672294
J Thorac Oncol. 2015 Aug;10(8):1133-41
pubmed: 26039012
PLoS One. 2020 Oct 26;15(10):e0240973
pubmed: 33104707
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
Nat Commun. 2018 Mar 13;9(1):1048
pubmed: 29535388
Arch Pathol Lab Med. 2019 Nov;143(11):1373-1377
pubmed: 30958693
Lung Cancer. 2019 Sep;135:73-79
pubmed: 31447005
Virchows Arch. 2017 Dec;471(6):713-720
pubmed: 28631159
Oncologist. 2019 Nov;24(11):e1172-e1179
pubmed: 31068386
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
Lung Cancer. 2018 Jan;115:116-120
pubmed: 29290251
J Thorac Dis. 2018 Feb;10(Suppl 3):S395-S396
pubmed: 29593884
Clin Cancer Res. 2019 Jan 1;25(1):210-221
pubmed: 30327311
J Hematol Oncol. 2019 Jun 18;12(1):61
pubmed: 31215500
Biochem Biophys Res Commun. 2019 Jun 30;514(3):853-860
pubmed: 31079917